345 related articles for article (PubMed ID: 35773148)
21. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
[TBL] [Abstract][Full Text] [Related]
22. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
23. Tumor Organoids: The Era of Personalized Medicine.
Rassomakhina NV; Ryazanova AY; Likhov AR; Bruskin SA; Maloshenok LG; Zherdeva VV
Biochemistry (Mosc); 2024 Jan; 89(Suppl 1):S127-S147. PubMed ID: 38621748
[TBL] [Abstract][Full Text] [Related]
24. Organoids: approaches and utility in cancer research.
Zhou B; Feng Z; Xu J; Xie J
Chin Med J (Engl); 2023 Aug; 136(15):1783-1793. PubMed ID: 37365679
[TBL] [Abstract][Full Text] [Related]
25. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.
Phan N; Hong JJ; Tofig B; Mapua M; Elashoff D; Moatamed NA; Huang J; Memarzadeh S; Damoiseaux R; Soragni A
Commun Biol; 2019; 2():78. PubMed ID: 30820473
[TBL] [Abstract][Full Text] [Related]
26. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
27. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients.
Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y
Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650
[TBL] [Abstract][Full Text] [Related]
28. 3D Tumor Models and Their Use for the Testing of Immunotherapies.
Boucherit N; Gorvel L; Olive D
Front Immunol; 2020; 11():603640. PubMed ID: 33362787
[TBL] [Abstract][Full Text] [Related]
29. Cancer modeling meets human organoid technology.
Tuveson D; Clevers H
Science; 2019 Jun; 364(6444):952-955. PubMed ID: 31171691
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer organoids and their applications for precision cancer immunotherapy.
Guan D; Liu X; Shi Q; He B; Zheng C; Meng X
World J Surg Oncol; 2023 Oct; 21(1):343. PubMed ID: 37884976
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
32. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY
Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597
[TBL] [Abstract][Full Text] [Related]
33. Tumor organoids: From inception to future in cancer research.
Yang L; Yang S; Li X; Li B; Li Y; Zhang X; Ma Y; Peng X; Jin H; Fan Q; Wei S; Liu J; Li H
Cancer Lett; 2019 Jul; 454():120-133. PubMed ID: 30981763
[TBL] [Abstract][Full Text] [Related]
34. Organoid technology in cancer precision medicine.
Xia X; Li F; He J; Aji R; Gao D
Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
[TBL] [Abstract][Full Text] [Related]
35. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
[TBL] [Abstract][Full Text] [Related]
36. An emerging role for cytopathology in precision oncology.
Pauli C; Puca L; Mosquera JM; Robinson BD; Beltran H; Rubin MA; Rao RA
Cancer Cytopathol; 2016 Mar; 124(3):167-73. PubMed ID: 26641771
[TBL] [Abstract][Full Text] [Related]
37. Next generation patient derived tumor organoids.
Podaza E; Kuo HH; Nguyen J; Elemento O; Martin ML
Transl Res; 2022 Dec; 250():84-97. PubMed ID: 35964899
[TBL] [Abstract][Full Text] [Related]
38. Organoid technology and applications in cancer immunotherapy and precision medicine.
Homicsko K
Curr Opin Biotechnol; 2020 Oct; 65():242-247. PubMed ID: 32603978
[TBL] [Abstract][Full Text] [Related]
39. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
40. Emerging organoid models: leaping forward in cancer research.
Fan H; Demirci U; Chen P
J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
